Last Updated : April 16, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name Sort descending | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Myozyme | Alglucosidase | Pompe's disease | List with clinical criteria and/or conditions | Complete | ||
| Praluent | Alirocumab | Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rasilez | Aliskiren | Hypertension | Do not list | Complete | ||
| Toctino | Alitretinoin | Eczema | List with clinical criteria and/or conditions | Complete | ||
| Axert | Almotriptan | Migraine | List in a similar manner to other drugs in class | Complete | ||
| Nesina | Alogliptin | Diabetes mellitus, type 2 | Do not list | Complete | ||
| Kazano | Alogliptin plus metformin | Diabetes mellitus, type 2 | Do not list | Complete | ||
| Piqray | alpelisib | Advanced or Metastatic Breast Cancer | Do not reimburse | Complete | ||
| Zemaira | Alpha1-proteinase inhibitor (Human) | Severe Alpha1-proteinase inhibitor deficiency | Reimburse with clinical criteria and/or conditions | Complete | ||
| Volibris | Ambrisentan | Pulmonary arterial hypertension (WHO class II and III) | List with clinical criteria and/or conditions | Complete |
Last Updated : April 16, 2024